Streamex (STEX)
Develops commodity-tokenization infrastructure alongside the PURE EP electrophysiology platform.
Something off on this page? Send us feedback.
Develops a blockchain-based platform for commodity real-world-asset tokenization and exchange alongside the legacy PURE EP electrophysiology business. The RWA platform was development-stage and had no revenue at the latest year-end.
Combines a development-stage commodity real-world-asset platform, acquired through Streamex Exchange, with BioSig's inherited PURE EP biomedical business. Streamex Exchange had developed digital tools for commodity trading and finance in Vancouver; the issuer later adopted the Streamex name and STEX ticker.
The blockchain-based platform is designed for compliant tokenization and exchange, and GLDY launched after the reporting period with subscriptions beginning thereafter. PURE EP remains focused on advanced signal acquisition and processing for electrophysiology. Future platform revenue depends on platform maturity, regulatory developments, market conditions, adoption and issuance volumes, and monetizing GLDY and other tokenized products through fees.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Nov 25, 2025 | Needham | Target | Target: — | Target: $12 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $20.3M · Total debt $800.0K · Total assets $159.6M · Shareholders' equity $145.7M
- Revenue
- $146.0K
- Operating income
- −$15.2M
- Net income
- −$14.6M
No dividends on record.
| Insiders | 6.93% | 7.23M shares | |
|---|---|---|---|
| 10 holders · as of Sep 3, 2026 | |||
| Other | 93.07% | 97.04M shares | |
| remainder | |||
104.27M company shares as of Sep 22, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Mitchell Young WilliamsInsiderdirector, officer: Chief Investment Officer | 2.77% | 2.89M | filed Sep 3, 2026 |
Frank GiustraInsider10 percent owner | 1.23% | 1.28M | filed Feb 4, 2026 |
Karl Henry Michael McPhieInsiderdirector, officer: CEO | 0.93% | 969,389 | filed Apr 17, 2026 |
Morgan Lee LekstromInsiderdirector, officer: Interim Executive Chairman | 0.55% | 569,241 | filed Jun 15, 2026 |
Christine Marie PlummerInsiderofficer: Chief Financial Officer | 0.47% | 486,497 | filed Apr 17, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 2, 2026 | Mitchell Young Williams | director, officer: Chief Investment Officer | −72,689 | $0.7200 |
| Jun 12, 2026 | Morgan Lee Lekstrom | director, officer: Interim Executive Chairman | +50,000 | $0.9950 |
| Jun 1, 2026 | Mitchell Young Williams | director, officer: Chief Investment Officer | −23,810 | $1.05 |
| May 28, 2026 | Morgan Lee Lekstrom | director, officer: Interim Executive Chairman | +34,000 | $1.47 |
| Jan 23, 2026 | Morgan Lee Lekstrom | director, officer: Interim Executive Chairman | +88,000 | $3.13 |
- WisdomTree
Tokenized physical-gold issuance and spending infrastructure
- Figure
Blockchain-native RWA issuance, funding, and secondary markets
- Johnson & Johnson
3D electroanatomical mapping for catheter ablation
- Abbott
EP mapping platform for RF and pulsed-field ablation
- Circle
Tokenized-fund issuance and onchain collateral infrastructure
- Boston Scientific
Integrated EP mapping and navigation for RF and PFA
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Streamex | $0.7800 | +8.38% | $75.0M | — | — | 513.5 | — |
| WisdomTree | $23.16 | −2.34% | $3.63B | — | 19.2 | — | +57.3% |
| Figure | $35.83 | +1.53% | $6.44B | 46.4 | 26.9 | 9.0 | +95.2% |
| Johnson & Johnson | $268.88 | −0.22% | $649.40B | 31.2 | 22.7 | 6.6 | +6.6% |
| Abbott | $104.28 | +1.26% | $178.18B | 33.1 | 18.0 | 3.8 | +13.0% |
| Circle | $93.72 | −0.81% | $25.26B | 50.3 | — | 8.7 | +6.6% |
| Boston Scientific | $44.69 | +2.22% | $64.98B | 17.8 | 13.6 | 3.1 | +7.5% |
| Median | 33.1 | 19.2 | 6.6 | +10.3% |